Cigna GLP-1 Coverage in Washington: The 2026 Guide

Cigna uses Express Scripts (ESI) as its pharmacy benefit manager — the same company managing formularies, processing prior authorizations, and setting tier placements for most Cigna commercial plans. Cigna has updated its GLP-1 policies (IP0206 and IP0621) as of March 2026, and the result is a coverage framework that differs from most other major carriers in a few important ways.

Three things make Cigna distinctly different from carriers like Premera, Regence, or UnitedHealthcare: an 8-month initial approval period instead of the standard 12 months, a semaglutide-first step therapy requirement before Zepbound, and a policy emphasis on prescriber specialization. This guide explains all three — and how to navigate them as a Washington state Cigna member.

Cigna GLP-1 Coverage at a Glance

Cigna's 8-Month Initial Approval: What It Means

Most insurance carriers approve GLP-1 prior authorizations for 12 months on the initial approval. Cigna is the exception: for obesity GLP-1 medications (Wegovy and Zepbound), Cigna approves the first PA for only 8 months. At the 8-month mark, you must show at least 5% body weight loss from your pre-treatment baseline — or the authorization will not be renewed.

Semaglutide-First Step Therapy

For obesity GLP-1 coverage, Cigna requires a trial of semaglutide (Wegovy) before it will approve tirzepatide (Zepbound). This is the same step therapy approach used by Kaiser Permanente and some other carriers — you must try the preferred product first, and demonstrate inadequate response, before Cigna will move to Zepbound.

There is an exception pathway: if you have a documented clinical contraindication to semaglutide — persistent nausea or vomiting that prevents dose escalation beyond initial doses, a personal or family history that raises thyroid concerns, or another clinically documented intolerance — Cigna will consider Zepbound without requiring a prior Wegovy trial. The contraindication must be documented in the clinical record with specificity.

Clinical framing: if you haven't tried GLP-1 therapy before and have Cigna with an AOM rider, starting with Wegovy and then potentially transitioning to Zepbound is a reasonable and well-supported clinical path. Many patients do well on Wegovy long-term. For those who need to switch, the documentation from the Wegovy trial becomes the basis for the Zepbound authorization.

The "Specialized Skills" Requirement

Cigna policy IP0621 notes that prescribers should have the "specialized skills required for evaluation and diagnosis" in the conditions being treated. This language appears specifically in the context of GLP-1 prescribing for metabolic conditions. In practice, this means Cigna may review GLP-1 prescriptions from general practitioners or non-specialist providers with greater scrutiny than those from providers with demonstrable metabolic or hormonal expertise.

Revive's naturopathic physicians specialize specifically in hormone and metabolic therapy — testosterone, thyroid, GLP-1, and related systems. This specialization satisfies Cigna's prescriber expertise standard and is documented in our clinical credentials. Patients who come to Revive from general practitioners often find their Cigna PA process goes more smoothly because the prescribing provider's specialization is evident.

The CV Risk Pathway at Cigna

Wegovy for cardiovascular risk reduction is covered by Cigna, but the coverage criteria are more specific than many other carriers. Cigna requires documented established cardiovascular disease — specifically a prior myocardial infarction (heart attack), prior ischemic stroke, or symptomatic peripheral arterial disease (claudication, ankle-brachial index below 0.9, or prior peripheral revascularization procedure).

Cardiovascular risk factors alone — elevated blood pressure, high cholesterol, obesity, smoking history — are not sufficient for Cigna's CV indication. You must have established, documented cardiovascular disease meeting one of those three criteria. The approval is 12 months and does not require an AOM rider, making this a meaningful pathway for patients who have the qualifying CV history.

Zepbound for OSA at Cigna

Cigna covers Zepbound for obstructive sleep apnea with prior authorization. Requirements: sleep study showing AHI ≥15 (moderate-to-severe OSA), BMI ≥30, and confirmation that the apnea is obstructive rather than central. Approval period is 12 months. Critically, no AOM (anti-obesity medication) rider is required for the OSA indication.

This is an important pathway for Cigna members who don't have an AOM rider on their plan but have sleep apnea and obesity. If you have a documented sleep study confirming moderate-to-severe OSA and a BMI ≥30, Zepbound for OSA may be accessible through Cigna's standard PA process — bypassing both the step therapy requirement and the AOM rider requirement that applies to the obesity indication.

Estimated Patient Costs

Common Questions From Cigna Members

Does Cigna renew GLP-1 approvals automatically?

No. At 8 months (initial approval) and every 12 months thereafter (renewal), Cigna requires updated documentation showing at least 5% weight loss from the pre-treatment baseline. Your provider needs to submit renewal documentation proactively — ideally 2–4 weeks before the PA expiry date. Gaps in coverage can occur if renewal documentation is submitted late. At Revive, we track PA expiry dates and initiate renewal preparation well ahead of schedule.

My Cigna plan doesn't cover weight loss GLP-1s. Can I still get covered?

Potentially, through alternative indications. If you have established cardiovascular disease — a prior heart attack, prior stroke, or symptomatic peripheral arterial disease — Wegovy may be covered for CV risk reduction without an AOM rider. If you have obstructive sleep apnea confirmed by sleep study with AHI ≥15 and BMI ≥30, Zepbound may be covered via the OSA indication without an AOM rider. Neither pathway requires the weight management benefit to be active on your plan.

Does my Cigna prescriber need special credentials?

No special license is required, but Cigna's policy language calls for prescribers with metabolic and hormonal expertise. Revive physicians specialize specifically in hormone and metabolic therapy — testosterone, thyroid, GLP-1, and related systems. This specialization is clearly documented and satisfies Cigna's prescriber expertise standard.

Related GLP-1 Coverage Guides

• GLP-1 Insurance Coverage in Washington: The 2026 Complete Guide
• Premera Blue Cross GLP-1 Coverage in Washington 2026
• Regence GLP-1 Coverage in Washington 2026
• Kaiser Permanente GLP-1 Coverage in Washington 2026
• UnitedHealthcare GLP-1 Coverage in Washington 2026